Ulipristal Acetate is indicated for emergency contraception within 120 hours (5 days) after unprotected sexual intercourse or contraceptive failure.

Ulipristal Acetate 30 mg tablet is an emergency contraceptive pill used to prevent unintended pregnancy. It is a Selective Progesterone Receptor Modulator (SPRM). The tablet is intended for oral administration. Inactive ingredients include lactose monohydrate, povidone K-30, croscarmellose sodium, and magnesium stearate.

Ulipristal Acetate is an orally active synthetic SPRM that binds with high affinity to human progesterone receptors. Its primary mechanism of action is inhibition or delay of ovulation. Studies show that even when taken shortly before ovulation, it may delay follicular rupture in some women.

One 30 mg tablet must be taken as soon as possible but no later than 120 hours of unprotected intercourse or contraceptive failure, with or without food. If vomiting occurs within 3 hours of intake, then another tablet needed to be taken. Ulipristal Acetate can be taken at any time of menstrual cycle

Ulipristal Acetate may interact with drugs such as barbiturates, carbamazepine, phenobarbital, rifampicin, itraconazole, and ketoconazole, which can alter its effectiveness.

Ulipristal Acetate is contraindicated in patients with hypersensitivity to the active substance and in confirmed or suspected pregnancy.

Common side effects include headache, nausea, abdominal pain, dysmenorrhea, fatigue, dizziness, and breast tenderness.

Ulipristal Acetate is contraindicated during existing or suspected pregnancy. It is excreted into breast milk; therefore, breastfeeding is not recommended for one week after administration. Limited data are available regarding fetal or newborn exposure.

Existing Pregnancy: Ulipristal Acetate is not intended for termination of an existing pregnancy.

Ectopic Pregnancy: Previous ectopic pregnancy is not a contraindication.

Repeated Use: This medicine is intended for occasional emergency contraception and should not replace regular contraceptive methods. Repeated use within the same menstrual cycle is not recommended.

Fertility Following Use: Fertility may return rapidly after treatment; therefore, barrier contraception such as condoms should be used for subsequent intercourse.

Effect on Menstrual Cycle: Menstruation may occur earlier or later than expected. If menstruation is delayed by more than one week, pregnancy testing is recommended. Intermenstrual bleeding may occur in some women.

Children and Adolescents: Limited safety and efficacy data are available in females under 18 years of age.

Hepatic Impairment: No studies have evaluated the effect of liver disease on Ulipristal Acetate.

Renal Impairment: No studies have evaluated the effect of kidney disease on Ulipristal Acetate.

Experience with overdose is limited. In clinical studies, doses up to four times the recommended amount were administered without significant adverse reactions.

Drugs acting on the uterus, Emergency Contraceptive Pill

Store in a cool and dry place, protected from sunlight. Do not freeze. Keep out of the reach of children.